A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
A phase 1/2 trial of Ris-Rez in sarcomas, run by GlaxoSmithKline, now recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) is a phase 1/2 interventional study registered as NCT07602777 by GlaxoSmithKline, with 113 participants planned, started 2026-06-22 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ris-Rez and G-CSF.
Similar pages
not linked directly; found by shared links- TrialClinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialFirst-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
- TrialA Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Shares GSK and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares GSK and the tag pipeline.
- TrialFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Shares GSK and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK and the tag pipeline.
- TrialExtended Access of Momelotinib in Adults With Myelofibrosis
Shares GSK and the tag pipeline.